Nelotanserin

Nelotanserin
Nelotanserin
Systematic (IUPAC) name
1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
Clinical data
Pregnancy cat.  ?
Legal status  ?
Routes Oral
Identifiers
CAS number 839713-36-9 YesY
ATC code None
PubChem CID 11683556
ChemSpider 9858284 N
UNII 4ZA73QEW2P N
Chemical data
Formula C18H15BrF2N4O2 
Mol. mass 437.238 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Nelotanserin (APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A.[1] APD-125 was shown to be effective and well tolerated in clinical trials,[2][3] but development was halted in December 2008 because the substance did not meet the trial's endpoints.[4] Research continues on newer analogues which may potentially be more successful.[5]



References

  1. ^ Teegarden, B. R.; Li, H.; Jayakumar, H.; Strah-Pleynet, S.; Dosa, P. I.; Selaya, S. D.; Kato, N.; Elwell, K. H. et al. (2010). "Discovery of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin) and Related 5-Hydroxytryptamine2AInverse Agonists for the Treatment of Insomnia". Journal of Medicinal Chemistry 53 (5): 1923. doi:10.1021/jm9007328. PMID 20143782.  edit
  2. ^ Rosenberg, R; Seiden, DJ; Hull, SG; Erman, M; Schwartz, H; Anderson, C; Prosser, W; Shanahan, W et al. (2008). "APD125, a selective serotonin 5-HT2A receptor inverse agonist, significantly improves sleep maintenance in primary insomnia". Sleep 31 (12): 1663–71. PMC 2603489. PMID 19090322. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2603489. 
  3. ^ Al-Shamma, H. A.; Anderson, C.; Chuang, E.; Luthringer, R.; Grottick, A. J.; Hauser, E.; Morgan, M.; Shanahan, W. et al. (2009). "Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2A Inverse Agonist for the Treatment of Insomnia". Journal of Pharmacology and Experimental Therapeutics 332 (1): 281. doi:10.1124/jpet.109.160994. PMID 19841476.  edit
  4. ^ APD125 for Insomnia
  5. ^ Xiong, Y.; Ullman, B.; Choi, J. S. K.; Cherrier, M.; Strah-Pleynet, S.; Decaire, M.; Dosa, P. I.; Feichtinger, K. et al. (2010). "Synthesis and in Vivo Evaluation of Phenethylpiperazine Amides: Selective 5-Hydroxytryptamine2A Receptor Antagonists for the Treatment of Insomnia". Journal of Medicinal Chemistry 53 (15): 5696. doi:10.1021/jm100479q. PMID 20684606.  edit